Literature DB >> 9086127

Immunologic responses to vaccinia vaccines administered by different parenteral routes.

D J McClain1, S Harrison, C L Yeager, J Cruz, F A Ennis, P Gibbs, M S Wright, P L Summers, J D Arthur, J A Graham.   

Abstract

To develop a less reactogenic but equally immunogenic vaccine, this study of 91 human volunteers compared the safety and immunogenic potency of a new, cell culture-derived vaccinia virus vaccine administered intradermally and intramuscularly with the licensed vaccinia vaccine administered by scarification. Cutaneous pox lesions developed in a higher proportion of scarification vaccinees. Scarification and intradermal vaccine recipients who developed cutaneous pox lesions had more local reactions but also achieved significantly higher cell-mediated and neutralizing antibody responses than those who did not develop pox lesions. Although less reactogenic, intradermal or intramuscular administration of vaccinia vaccine without the concomitant development of a cutaneous pox lesion induced lower immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086127     DOI: 10.1086/513968

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  A stimulating way to improve T cell responses to poxvirus-vectored vaccines.

Authors:  Stuart N Isaacs
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Authors:  Benedikt Asbach; Karen V Kibler; Josef Köstler; Beatriz Perdiguero; Nicole L Yates; Sherry Stanfield-Oakley; Georgia D Tomaras; Shing-Fen Kao; Kathryn E Foulds; Mario Roederer; Michael S Seaman; David C Montefiori; Robert Parks; Guido Ferrari; Donald N Forthal; Sanjay Phogat; James Tartaglia; Susan W Barnett; Steven G Self; Raphael Gottardo; Anthony D Cristillo; Deborah E Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Bertram L Jacobs; Giuseppe Pantaleo; Ralf Wagner
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 3.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

5.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Authors:  Nicole L Garza; Josh M Hatkin; Virginia Livingston; Donald K Nichols; Paul J Chaplin; Ariane Volkmann; Diana Fisher; Aysegul Nalca
Journal:  Vaccine       Date:  2009-07-24       Impact factor: 4.169

7.  Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

Authors:  K S Slobod; T D Lockey; N Howlett; R V Srinivas; S D Rencher; P J Freiden; P C Doherty; J L Hurwitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

8.  Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Authors:  Richard Kennedy; V Shane Pankratz; Eric Swanson; David Watson; Hana Golding; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

9.  Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus.

Authors:  Tian Tian; Luzheng Liu; Eva-Jasmin Freyschmidt; George F Murphy; Thomas S Kupper; Robert C Fuhlbrigge
Journal:  J Invest Dermatol       Date:  2008-07-10       Impact factor: 8.551

10.  The smallpox vaccine induces an early neutralizing IgM response.

Authors:  Juan E Moyron-Quiroz; Megan M McCausland; Robin Kageyama; Alessandro Sette; Shane Crotty
Journal:  Vaccine       Date:  2009-10-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.